1. Melmed S. Acromegaly. N. Engl. J. Med. 1990, 322: 966–977.
2. Vance M.L., Harris A.G. Long-term treatment of 189 acromegalic patients with the somatostatin analogue octreotide, results of the international multicentre acromegaly study group. Arch. Intern. Med. 1991, 151: 1573–1578.
3. Newman C.B., Melmed S., Snyder P.J., Young W.F., Boyajy L.D., Levy R., Stewart W.N., Klibanski A., Molitch M., Gagel R.F., Boyd A.E., Sheeler L., Cook D., Malarkey W.B., Jackson I.M.D., Vance M.L., Thorner M.O., Ho P.J., Jaffe C.A., Frohman L.A., Kleinberg D.L. Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicentre trial in 103 patients. J. Clin. Endocrinol. Metab. 1995, 80: 2768–2775.
4. Stewart P.M., Kane K.F., Stewart S.E., Lancranjan I., Sheppard M.C. Depot long-Acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J. Clin. Endocrinol. Metab. 1995, 80: 3267–3272.
5. Fløgusted A.K., Halse J., Bakke S. Sandostatin LAR in acromegalic patients: Long term treatment. J. Clin. Endocrinol. Metab. 1997, 82: 23–28.